The manufacture of finished doses will commence in 2022 and at full operational capacity, the annual production is expected to exceed 100 million doses annually
Domestic business was up 41.9% YoY and 27.7% QoQ
Serum buys 50 per cent stake in Indian joint venture of SCHOTT Kaisha
Domestic formulations business records 39 % growth while the international business revenue was largely flat as compared to Q1 FY21
This robust performance is a testimony of the company's agility, resilience and strong execution capabilities during these difficult times
Partnership enables broad reach of cfDNA methylation blood tests for early cancer detection
Filing for WHO Emergency Use Authorisation this month
Deal for 100 million doses with additional 100 million through 2023
It is part of the company’s pain/analgesics portfolio of OTC products
The company posted net profit of Rs.89.20 crores for the period ended June 30, 2020.
Subscribe To Our Newsletter & Stay Updated
